Literature DB >> 19738020

Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.

Anne-Sylvie Kesteman1, Aude A Ferran, Agnès Perrin-Guyomard, Michel Laurentie, Pascal Sanders, Pierre-Louis Toutain, Alain Bousquet-Mélou.   

Abstract

We tested the hypothesis that the bacterial load at the infection site could impact considerably on the pharmacokinetic/pharmacodynamic (PK/PD) parameters of fluoroquinolones. Using a rat lung infection model, we measured the influence of different marbofloxacin dosage regimens on selection of resistant bacteria after infection with a low (10(5) CFU) or a high (10(9) CFU) inoculum of Klebsiella pneumoniae. For daily fractionated doses of marbofloxacin, prevention of resistance occurred for an area-under-the-concentration-time-curve (AUC)/MIC ratio of 189 h for the low inoculum, whereas for the high inoculum, resistant-subpopulation enrichment occurred for AUC/MIC ratios up to 756 h. For the high-inoculum-infected rats, the AUC/MIC ratio, C(max)/MIC ratio, and time within the mutant selection window (T(MSW)) were not found to be effective predictors of resistance prevention upon comparison of fractionated and single administrations. An index corresponding to the ratio of the time that the drug concentrations were above the mutant prevention concentration (MPC) over the time that the drug concentrations were within the MSW (T(>MPC)/T(MSW)) was the best predictor of the emergence of resistance: a T(>MPC)/T(MSW) ratio of 0.54 was associated with prevention of resistance for both fractionated and single administrations. These results suggest that the enrichment of resistant bacteria depends heavily on the inoculum size at the start of an antimicrobial treatment and that classical PK/PD parameters cannot adequately describe the impact of different dosage regimens on enrichment of resistant bacteria. We propose an original index, the T(>MPC)/T(MSW) ratio, which reflects the ratio of the time that the less susceptible bacterial subpopulation is killed over the time that it is selected, as a potentially powerful indicator of prevention of enrichment of resistant bacteria. This ratio is valid only if plasma concentrations achieve the MPC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738020      PMCID: PMC2772313          DOI: 10.1128/AAC.00608-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

Review 4.  Stretching the mutant prevention concentration (MPC) beyond its limits.

Authors:  Heather J Smith; Kimberly A Nichol; Daryl J Hoban; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

5.  Clarification of MPC and the mutant selection window concept.

Authors:  Xilin Zhao
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

6.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

8.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.

Authors:  Arnold Louie; David L Brown; Weiguo Liu; Robert W Kulawy; Mark R Deziel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

10.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more
  14 in total

1.  Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Authors:  Anne-Sylvie Kesteman; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Authors:  Maleck V Vasseur; Michel Laurentie; Jean-Guy Rolland; Agnès Perrin-Guyomard; Jérôme Henri; Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

4.  Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection.

Authors:  Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Vet Microbiol       Date:  2010-09-15       Impact factor: 3.293

5.  A New Pharmacokinetic-Pharmacodynamic Model To Characterize the Inoculum Effect of Acinetobacter baumannii on Polymyxin B In Vitro.

Authors:  Grace Akrong; Alexia Chauzy; Vincent Aranzana-Climent; Mathilde Lacroix; Luc Deroche; Laure Prouvensier; Julien M Buyck; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.938

6.  Experimental model for treatment of extended spectrum betalactamase producing-Klebsiella pneumoniae.

Authors:  Paula Virginia Michelon Toledo; Felipe Francisco Tuon; Larissa Bail; Francine Manente; Polliane Arruda; Ayrton Alves Aranha-Junior
Journal:  Arq Bras Cir Dig       Date:  2014 Jul-Sep

7.  Prediction of Minocycline Activity in the Gut From a Pig Preclinical Model Using a Pharmacokinetic -Pharmacodynamic Approach.

Authors:  Quentin Vallé; Béatrice B Roques; Alain Bousquet-Mélou; David Dahlhaus; Felipe Ramon-Portugal; Véronique Dupouy; Delphine Bibbal; Aude A Ferran
Journal:  Front Microbiol       Date:  2021-07-09       Impact factor: 5.640

8.  Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies.

Authors:  Guillaume Lhermie; Farid El Garch; Pierre-Louis Toutain; Aude A Ferran; Alain Bousquet-Mélou
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

9.  Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.

Authors:  Guillaume Lhermie; Aude A Ferran; Sébastien Assié; Hervé Cassard; Farid El Garch; Marc Schneider; Frédérique Woerhlé; Diane Pacalin; Maxence Delverdier; Alain Bousquet-Mélou; Gilles Meyer
Journal:  Front Microbiol       Date:  2016-03-02       Impact factor: 5.640

10.  Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.

Authors:  Ying Qu; Zhenzhen Qiu; Changfu Cao; Yan Lu; Meizhen Sun; Chaoping Liang; Zhenling Zeng
Journal:  BMC Vet Res       Date:  2015-12-02       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.